Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Keros Therapeutics

Request full access

Keros Therapeutics, Inc. operates as a biotechnology company

Lexington, United StatesFounded 2015Biotech & Life Sciences

About Keros Therapeutics

Keros Therapeutics is a biopharmaceutical startup that operates in the healthcare sector, specifically in the development of innovative therapies. The company's primary focus is on disorders linked to the dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. In simpler terms, they are working on treatments that can help the body's cells grow and repair themselves more effectively, particularly blood cells and various tissues.

Their business model revolves around leveraging their deep expertise in TGF-ß science to develop and commercialize novel therapeutics. These therapeutics have the potential to modulate TGF-ß signaling, which could provide disease-modifying benefits for patients. This means they are creating new drugs that can potentially change how diseases progress, offering significant benefits to patients.

The company's target market includes patients with disorders linked to the dysfunctional signaling of TGF-ß proteins. This could potentially cover a wide range of patients, given the fundamental role these proteins play in cellular growth and repair.

Keros Therapeutics generates revenue through the development and commercialization of these novel therapeutics. Once a therapy is developed and approved, it can be sold to healthcare providers who administer it to patients. The company's potential for revenue growth lies in the successful development and approval of their therapies, as well as the size of the patient population that could benefit from these treatments.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020

Keros Therapeutics in the Lexington ecosystem

Live from Dealroom

The Keros Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Pontifax Funds
  • Global health sciences venture fund
  • Partners Innovation Fund
  • Medison Pharma

Series B and later3 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇩🇰 Denmark0.9%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Keros Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Keros Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.